Details for New Drug Application (NDA): 214522
✉ Email this page to a colleague
The generic ingredient in TADLIQ is tadalafil. There are twenty-five drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the tadalafil profile page.
Summary for 214522
Tradename: | TADLIQ |
Applicant: | Cmp Dev Llc |
Ingredient: | tadalafil |
Patents: | 3 |
Pharmacology for NDA: 214522
Mechanism of Action | Phosphodiesterase 5 Inhibitors |
Medical Subject Heading (MeSH) Categories for 214522
Suppliers and Packaging for NDA: 214522
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
TADLIQ | tadalafil | SUSPENSION;ORAL | 214522 | NDA | CMP Pharma, Inc. | 46287-045 | 46287-045-15 | 150 mL in 1 BOTTLE (46287-045-15) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SUSPENSION;ORAL | Strength | 20MG/5ML | ||||
Approval Date: | Jun 17, 2022 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Dec 24, 2038 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | TADLIQ IS INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO IMPROVE EXERCISE ABILITY | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Dec 24, 2038 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | TADLIQ IS INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO IMPROVE EXERCISE ABILITY | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Dec 24, 2038 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | TADLIQ IS INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO IMPROVE EXERCISE ABILITY |
Complete Access Available with Subscription